NasdaqCM:DNTHBiotechs
Dianthus Therapeutics (DNTH) Is Up 6.2% After Early CAPTIVATE “GO” Decision And FDA Alignment - Has The Bull Case Changed?
Dianthus Therapeutics recently reported an early “GO” decision in its late-stage CAPTIVATE trial of claseprubart for chronic inflammatory demyelinating polyneuropathy, after meeting interim responder goals ahead of schedule.
The US FDA also agreed to multiple company-proposed changes across claseprubart’s development program, including updated screening criteria, lab work, and autoimmune safety monitoring, potentially streamlining current and future studies.
We’ll now examine how the early...